Novel agent for treatment of Parkinson's disease - Lu 02-750
- Details
- Category: Lundbeck
H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. The placebo-controlled study is expected to enrol around 100 healthy individuals.
Novo Nordisk increased operating profit by 30% in the first nine months of 2009
- Details
- Category: Novo Nordisk
Sales increased by 15% in Danish kroner and by 11% in local currencies:
-
Sales of modern insulins increased by 28% (24% in local currencies).
Sales of NovoSeven® increased by 15% (11% in local currencies).
Sales of Norditropin® increased by 15% (9% in local currencies).
Sales in North America increased by 29% (17% in local currencies).
Sales in International Operations increased by 18% (16% in local currencies).
AstraZeneca PLC Third Quarter & Nine Months Results 2009
- Details
- Category: AstraZeneca
Revenue in the third quarter increased by 10 percent at CER, but was up 5 percent on an actual basis as a result of the negative impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); adjusting for these factors, global revenue increased by 5 percent.
Abbott completes acquisition acquisition of privately held eye care company Visiogen
- Details
- Category: Abbott
Abbott (NYSE: ABT) has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.
Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase IIb Study of Cariprazine
- Details
- Category: Clinical Trials
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.
Pandemrix data in an elderly population
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine, Pandemrix™, as part of Government initiated vaccination programmes across Europe, which commenced earlier this month. GSK also announced new results from a clinical trial assessing the use of Pandemrix in adults aged 18 to 85 years of age.
Boehringer Ingelheim Animal Health closes deal to acquire Animal Health Business from Pfizer
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business.
More Pharma News ...
- Novartis delivers strong new product momentum and operational performance
- Merck Revenues Increase by 2.7% to € 1.9 Billion
- FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity
- Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer
- Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer
- Bristol-Myers Squibb Achieves Strong Sales